Track Minerva Neurosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Minerva Neurosciences, Inc. NERV · Stock Open Minerva Neurosciences, Inc. in new tab

2.32 USD
P/E
2.65
EPS
-33.83
P/B
-1.31
Beta
0.01
Target Price
10.33 USD
Loading chart...
Key Metrics
Earnings dateMarch 10, 2027
P/E2.65
EPS-33.83
Book Value-1.96
Price to Book-1.31
% Insiders3.126%
Estimates
Forward P/E-6.10
Forward EPS-0.42
Target Mean Price10.33

DCF valuation

Model fair value for Minerva Neurosciences, Inc. (NERV)
Result
Sign in to run the valuation for NERV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Buy · mean target 10.33 USD (low 7.00, high 14.00) · as of 12 Nov 2026
Low 7.00
Mean 10.33
High 14.00
Price 2.32
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Minerva Neurosciences, Inc. Logo Minerva Neurosciences, Inc. Analysis (NERV)

United States Health Care Official Website Stock

Is Minerva Neurosciences, Inc. a good investment? Minerva Neurosciences, Inc. (NERV) is currently trading at 2.32 USD. Market analysts have a consensus price target of 10.33 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 2.65. This relatively low multiple may signal that Minerva Neurosciences, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Minerva Neurosciences, Inc. is expected to release its next earnings report on March 10, 2027. The market consensus estimate for Forward EPS is -0.42.

Investor FAQ

Does Minerva Neurosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Minerva Neurosciences, Inc.?

Minerva Neurosciences, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 10, 2027. The company currently has a trailing EPS of -33.83.

Company Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Exchange Ticker
FRA (Germany) 4MN.F
STU (Germany) 4MN.SG
NMS (United States) NERV
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 21, 2022 Needs review
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion